Navigation Links
Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
Date:5/27/2009

First clinical study evaluating DUROS(R) continuous delivery of exenatide for the treatment of type 2 diabetes

HAYWARD, Calif., May 27 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced it will present clinical data from a phase 1b study of ITCA 650 (DUROS(R) continuous delivery of exenatide) for the treatment of type 2 diabetes as a late-breaker at the Annual Conference of the American Diabetes Association in New Orleans, LA (June 5-9, 2009). The study was conducted at multiple centers in the United States and evaluated a 4-week course of ITCA 650 treatment among 44 patients (n= 10-12 patients/dose arm) with type 2 diabetes.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO)

ITCA 650 Late-Breaker Abstract 4-LB in Category 01-C Clinical Therapeutics/ New Technology - Other Drug Delivery Systems:

A Phase 1b Study of ITCA 650: Continuous Subcutaneous Delivery of Exenatide via DUROS(R) Device Lowers Fasting and Postprandial Plasma Glucose - Luskey, K., McNally, J., Dahms, J., Logan, D., Weiner, G., Denham, D. and Alessi, T.

"We are very pleased the ADA scientific reviewers selected our study for presentation as a late-breaker," said Alice Leung, President & CEO of Intarcia Therapeutics, Inc. "Our team worked very hard to advance this program from an idea to clinical evaluation in under 18 months. In continuing this brisk pace, we expect to begin a phase 2 study of ITCA 650 in the second half of this year."

The late-breaker abstract describes the dose-ranging design of the study and preliminary results from the two lower doses of 10mcg/day and 20 mcg/day through the first two weeks of treatment. Based on the favorable tolerability of DUROS continuous delivery of exenatide on the lower doses, patients have been enrolled to two higher d
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
2. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
3. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
4. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
5. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
6. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
7. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
8. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
9. Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
10. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
11. Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... , Aug. 18, 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: ... proprietary technologies and products for advanced microarray diagnostics, today ... Friday, August 22 at 2:00 pm ET.  ... will provide a brief review of SQI,s recent commercialization ... a diagnostics industry veteran recently appointed to the Board ...
(Date:8/18/2014)... HIV Infection Drug Market and Pipeline Insight is a ... infection and the number of deaths due to AIDS has ... the globe. It has been estimated that the death rate ... with the rates for children being even much lower. A ... has been the improved access to antiretroviral drugs and therapy ...
(Date:8/18/2014)... Fla. , Aug. 18, 2014 ... biotechnology company whose patented and proprietary technologies are ... other proteins for the bioenergy, bio-based chemical, biopharmaceutical ... has filed a Registration Statement on Form 10 ... "SEC"). Logo - http://photos.prnewswire.com/prnh/20110621/CL06708LOGO ...
(Date:8/16/2014)... $229,214 grant from the Walmart Foundation to build a ... cut the manufacturing costs of goods, allowing those goods ... formerly built overseas. , The Walmart U.S. Manufacturing Innovation ... in awards to seven research and development institutions at ... through the collaboration between Walmart, the U.S. Conference of ...
Breaking Biology Technology:SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4Dyadic International Files Form 10 Registration Statement 2Dyadic International Files Form 10 Registration Statement 3Dyadic International Files Form 10 Registration Statement 4UT Arlington receives Walmart, Walmart Foundation innovation grant 2UT Arlington receives Walmart, Walmart Foundation innovation grant 3
... ... software (OSS) in clinical trial electronic data capture and clinical data management. , ... Waltham, MA (PRWEB) January ... trial software, will gather on March 22nd, 2010 in Bethesda, Maryland (USA) for the ...
... ... over 24 years of experience to Professional Reprographics. , ... Irvine, California (PRWEB) January 7, 2010 -- Orange ... as President of Professional Reprographics. The naming of Cindy as President reflects Pro Repro’s ...
... , , , , SHENYANG, ... ), a leading biotechnology company focused on researching,developing, manufacturing ... it has submitted its application for a,registrational clinical trial ... Feraheme (ferumoxytol) Injection for intravenous,use. Feraheme is an intravenous ...
Cached Biology Technology:OpenClinica Global Conference to Bring Together Global Community for Open Source Clinical Trials Software 2OpenClinica Global Conference to Bring Together Global Community for Open Source Clinical Trials Software 3OpenClinica Global Conference to Bring Together Global Community for Open Source Clinical Trials Software 4Woman Owned Business President Makes Her Mark at Professional Reprographics 23SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM) 23SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM) 33SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM) 4
(Date:8/19/2014)... of today,s crocodiles colonised the seas during warm phases ... new Anglo-French study which establishes a link between marine ... a period of more than 140 million years. ... the Universit de Lyon, France and formerly from the ... Nature Communications ., Today, crocodiles are ,cold-blooded, animals ...
(Date:8/19/2014)... at the University of Liverpool has found how worms ... with the body. , Dr Paolo Paoletti, alongside his ... mathematical model for earthworms and insect larvae which challenges ... get around. , The most widely accepted model is ... that the central brain of these creatures generates rhythmic ...
(Date:8/19/2014)... in French . ... RISKS of physical activity in children,Today the Canadian Society ... of childhood physical activity and published their position and ... Metabolism ( APNM ). This position stand ... of risk of physical activity for children and suggests ...
Breaking Biology News(10 mins):Evolution of marine crocodilians constrained by ocean temperatures 2Secrets of how worms wriggle uncovered 2Taking a stand: Balancing the BENEFITS and RISKS of physical activity in children 2Taking a stand: Balancing the BENEFITS and RISKS of physical activity in children 3
... advance into the vanishingly small realm of molecules and ... venerable optical microscope, after all. In fact, research at ... that a hybrid version of the optical microscope might ... 10 nanometers—a tiny fraction of the wavelength of visible ...
... simple drug, given to children with severe malaria before they ... researchers in this week's BMJ. , Every year over a ... fatalities occur outside hospital, especially in rural areas. For those ... within 24 hours of admission. , Conventional treatment, given by ...
... potential new drug that inhibits destructive cell signals that ... scientists showed they could block the growth of cultured ... , Their finding, reported in the March 22, 2005, ... is the first step toward developing a new class ...
Cached Biology News:Devising Nano Vision for an Optical Microscope 2Newly Discovered Compound Blocks Known Cancer-Causing Protein 2Newly Discovered Compound Blocks Known Cancer-Causing Protein 3
Immunogen: Recombinant full length protein, corresponding to amino acids 1-435 of Human AP2M1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Anti-Dynamin Monoclonal Antibody Description: 100 g Research Focus: neuroscience Storage: -20C Shipping Temperature: 4C...
cysteine and glycine-rich protein 2,...
BKBeta2 potassium channel Antigen: Fusion protein amino acids 1-41 (N-terminus) and 218-235 (C-terminus) of mouse BKBeta2 Accession Number: Q9CZM9...
Biology Products: